Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
clinical trials
life sciences
national blog main
2
×
agios pharmaceuticals
alexion pharmaceuticals
alnylam pharmaceutials
arrowhead pharmaceuticals
boehringer ingelheim
boston
cancer
cancer drugs
david e. shaw
deals
dicerna pharmaceuticals
drug discovery
eli lilly
enasidenib
fda
hepatitis b
indiana blog main
indiana top stories
investing
ipo
ivosidenib
johnson & johnson
materials science
morphic
national top stories
neurodegenerative diseases
new york
new york blog main
new york top stories
nimbus therapeutics
primary hyperoxaluria
rna interference
san francisco blog main
san francisco top stories
What
development
2
×
medicines
2
×
abandoning
ago
baggage
companies
company’s
course
cuts
deal
dicerna
discover
experimental
free
gets
growing
handiwork
helped
interference
internal
ipo
landscape
long
pharma
pipeline
rna
rnai
scan
schrödinger
schrödinger’s
sets
signs
small
software
spot
support
today
wasn’t
you’ll
Language
unset
Current search:
medicines
×
development
×
" national blog main "
×
@xconomy.com
4 years ago
Schrödinger Sets Course for IPO to Support Growing Internal Pipeline
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M
